Breast cancer. Breast cancer is the most
common cancer among women worldwide. KalGene is developing
a breast cancer assay to classify breast cancer disease and identify a
new subgroup of breast cancer patients
who will benefit from specific, tailored therapy regimens. The assay also
includes novel molecular targets for
the development of new therapies.
Epithelial and thyroid cancers. Epithelial cancers make up 80-85% of
all cancers including breast, bladder,
lung, pancreas, thyroid and prostate cancers. Thyroid cancer is the most
common epithelial malignancy of
the endocrine glands. KalGene is developing a multi-protein assay to
identify aggressive epithelial cancers
including thyroid cancers. The proprietary molecular signature also contains
an exciting new drug target for the treatment of several, difficult
to treat epithelial cancers.
Bladder cancer. Bladder cancer is the seventh most diagnosed type of
cancer in the world, the fourth leading cancer among men and the ninth
most frequently diagnosed cancer among women. KalGene's lead therapeutic
is a late-stage product for preventing the recurrence of superficial
bladder cancer.
KalGene is evaluating additional innovative preclinical programs for
other cancers as well.
|
